3C
GBT

361 Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

361 Capital’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$582K Buy
+9,222
New +$633K 0.27% 204

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

361 Capital's GBT Position: Q2 2020 in Review

361 Capital opened a new position in Global Blood Therapeutics, Inc. (GBT) in Q2 2020: 9,222 shares worth $582K. The stake represents 0.27% of the portfolio and ranks #204 among its holdings.

253 funds tracked by Wall St. Rank hold GBT as of Q2 2020.

  • 361 Capital held 9,222 shares of Global Blood Therapeutics, Inc. worth $582K as of Q2 2020.
  • Global Blood Therapeutics, Inc. was a new 361 Capital position in Q2 2020.
  • Global Blood Therapeutics, Inc. made up 0.27% of 361 Capital's portfolio in Q2 2020, its #204 holding.
  • 253 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.